SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2019: Jan Feb
2019 - 2018 - 2017 - 2016

February 2019 Scleroderma News

Effects of treatment with rituximab on microcirculation in patients with long–term systemic sclerosis. Rituximab improves microcirculation in long–term SSc and stabilization and reduced progression of microcirculation abnormalities were achieved. PubMed, BMC Res Notes, 2018 Dec 10;11(1):874. (Also see Biologic Agents and Clinical Trials)

Median neuropathy at the wrist (MNW) in patients with systemic sclerosis (SSc): two–year follow–up study. MNW commonly has high incidence in SSc patients and therefore, SSc patients should be followed up in both clinical and electrodiagnostic studies for MNW screening. PubMed, Reumatologia, 2018;56(5):294-300. (Also see Hand and Joint Involvement)

Antinuclear Antibodies in Systemic Sclerosis: an Update. Autoantibodies specific for systemic sclerosis have been linked to distinct clinical features, so therefore, detecting a particular antibody type is important in predicting a possible organ involvement and prognosis. PubMed, Clin Rev Allergy Immunol, 01/03/2019. (Also see Antibodies)

Potential occupational and environmental factors in systemic sclerosis (SSc) onset. Although the pathogenesis of scleroderma remains unclear, there is a marked correlation between the onset of SSc and certain environmental or occupational factors. PubMed, Ann Agric Environ Med, 2018 Dec 19;25(4):596-601. (Also see Causes of Scleroderma: Environmental)

A TNFSF13B functional variant is not involved in systemic sclerosis (SSc) and giant cell arteritis (GCA) susceptibility. Our data suggest that the TNFSF13B functional variant does not contribute to the genetic network underlying GCA and SSc. PubMed, PLoS One, 2018 Dec 26;13(12):e0209343. (Also see Cytokines)

Ulnar Artery Occlusion (UAO) and severity markers of vasculopathy in Systemic sclerosis (SSc): a multicenter cross–sectional study. UAO may represent a relevant severity marker of the vasculopathy in SSc. PubMed, Arthritis Rheumatol, 12/15/2018. (Also see Vascular Involvement)

Phase 2a Trial Will Evaluate GLPG1690 in Diffuse Cutaneous Scleroderma. A Phase 2a clinical trial will test the investigational therapy GLPG1690 in patients with diffuse cutaneous scleroderma. Scleroderma News, 01/10/2019. (Also see Clinical Trials)

Performance of candidate serum biomarkers for systemic sclerosis–interstitial lung disease (SSc–ILD). Our results show that lung–epithelial–derived surfactant protein is a relevant diagnostic biomarker of SSc-ILD, whereas glycoprotein Krebs von den Lungen-6 could assess lung fibrosis severity. PubMed, Arthritis Rheumatol, 01/09/2019. (Also see Severity and Prognosis for Scleroderma Pulmonary Involvement)

Case Report: Systemic sclerosis and myositis as a paraneoplastic syndrome secondary to multiple myeloma (MM). To the best of our knowledge, this is the first case reporting these two clinical conditions simultaneously associated with MM. PubMed, Acta Reumatol Port. (Also see Myopathy and Myositis and Cancer)

An extended high–frequency ultrasound protocol for assessing and quantifying of inflammation and fibrosis in localized scleroderma (LoS). High–frequency ultrasound allows an accurate assessment of the inflammatory and fibrotic skin lesions in LoS. PubMed, Skin Res Technol, 01/14/2019. (Also see Skin Fibrosis and Localized Scleroderma)

Go to Scleroderma Medical News: January 2019
 

Many thanks to our recent donors, Jack and Elizabeth Lewis, Chris Dokter, Margaret Roof, Network for Good, PayPal Charitable Giving Fund, United Way Snohomish and Arnold Slotkin. See ISN News for more donors. Click Here to Donate.

 

TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.

We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, report bad links, or update page content. Disclaimer. Privacy Policy.
 

The most important thing in the world to know about scleroderma is sclero.org!

DONATE